Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
11.60
-0.66 (-5.38%)
NASDAQ · Last Trade: May 20th, 12:14 PM EDT
Detailed Quote
Previous Close
12.26
Open
12.00
Bid
11.40
Ask
11.75
Day's Range
10.77 - 12.37
52 Week Range
2.700 - 18.00
Volume
184,034
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
N/A (N/A)
1 Month Average Volume
134,709
Chart
About Quantum Biopharma Ltd. - Class B Subordinate Voting Shares (QNTM)
Quantum Biopharma Ltd. is a biotechnology company focused on developing innovative therapies and treatments for a range of diseases, leveraging advanced biopharmaceutical technologies. The company specializes in creating novel drugs and biologics aimed at improving patient outcomes and addressing unmet medical needs in various therapeutic areas. Through a combination of cutting-edge research and strategic partnerships, Quantum Biopharma is actively engaged in bringing its proprietary products from the lab to clinical trials, with the ultimate goal of enhancing healthcare options and improving the quality of life for patients worldwide. Read More
Quantum BioPharma (NASDAQ: QNTM) has signed an agreement with a global pharmaceutical contract research organization to prepare an Investigational New Drug (IND) application for its lead compound, Lucid-21-302 (Lucid-MS), targeting multiple sclerosis. The IND submission to the FDA is planned for the fourth quarter of 2025 and, if accepted, would enable the company to initiate a Phase 2 clinical trial. Lucid-21-302 is a patented, non-immunomodulatory neuroprotective therapy shown in preclinical studies to prevent demyelination, a key driver of MS and other neurodegenerative disorders.
TORONTO, May 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announces that it has signed an agreement with a global pharmaceutical contract research organization to prepare an IND (Investigational New Drug) application package for Lucid-21-302 (Lucid-MS) with the US FDA. A successful IND application will allow Quantum Biopharma to move forward with a Phase 2 trial of Lucid-21-302 in people with multiple sclerosis (MS).
The company increased its Bitcoin and cryptocurrency holdings to $4.5 million, reinforcing its strategy to hedge against currency fluctuations and improve shareholder value.
TORONTO, May 19, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval from the Board of Directors, the Company has purchased an additional USD $1,000,000 worth of Bitcoin (BTC) and other cryptocurrencies as part of its strategic efforts. This brings the total amount of BTC and other cryptocurrencies purchased to USD $4,500,000. As previously announced the company will continue to allow for future financing and other transactions to be carried out in cryptocurrency.
TORONTO, May 16, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”) a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that management will attend the Sidoti Micro-Cap Conference and the A.G.P. Virtual Healthcare Conference in May 2025.
Quantum BioPharma (NASDAQ: QNTM) announced the completion of dosing in 90-day oral toxicity and toxicokinetic studies for its lead candidate Lucid-21-302 (“Lucid-MS”), a novel treatment in development for multiple sclerosis. The results of these studies will support an Investigational New Drug (IND) application to the U.S. FDA, expected by year-end. Executives highlighted the milestone as a major step toward launching a Phase 2 clinical trial and positioning Lucid-21-302 as a first-in-class therapy for MS.
TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced that dosing of drug has completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS) for Multiple Sclerosis (“MS”). These studies were commissioned to provide data to support an IND application with the US FDA.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on innovative biotech solutions, has filed an amended complaint in the U.S. District Court for the Southern District of New York. The updated filing, made May 1, 2025, responds to a prior motion to dismiss and alleges that CIBC World Markets, RBC Dominion Securities and others engaged in spoofing and other manipulation tactics that violated federal securities laws between Jan. 1, 2020, and Aug. 15, 2024. The company is seeking damages of more than $700 million.
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to its Board of Directors. A seasoned financial advisor with over 40 years of family experience in wealth management, Malone is known for his work in market pattern recognition and his outspoken stance against trading manipulation. As founder of Malone Wealth, he champions financial literacy and advocates against naked short selling, a mission closely aligned with Quantum’s shareholder protection values and therapeutic focus.
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced it will host a Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern time to discuss its recent year-end financial results, regulatory initiatives, commercial-readiness activities and anticipated milestones.
Quantum BioPharma (NASDAQ: QNTM) has appointed Kevin Malone as an advisor to its Board of Directors. A seasoned financial advisor with over 40 years of family experience in wealth management, Malone is known for his work in market pattern recognition and his outspoken stance against trading manipulation. As founder of Malone Wealth, he champions financial literacy and advocates against naked short selling, a mission closely aligned with Quantum’s shareholder protection values and therapeutic focus.
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone as an advisor to the Board of Directors. Mr. Malone brings a vast wealth of successful stock trading experience, especially in manipulated companies, from his years of wealth management.
Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. The company recently announced corporate updates, including the grant of 60,000 restricted share units (each, an “RSU”) pursuant to its equity incentive plan, which are subject to certain vesting criteria. In addition, Quantum BioPharma announced that its board of directors authorized and approved the settlement of outstanding debt owed to arm’s length parties by issuing Class B Shares, each at a deemed price of US$6.75.
In this video lesson, I look at the overall market, what I expect the market to do in the intermediate term, my game plan per all my time frames and accounts.
Quantum BioPharma (NASDAQ: QNTM), a biopharmaceutical company focused on neurodegenerative, metabolic and alcohol misuse disorders, announced that a reconsideration motion filed by former CEO Dr. Raza Bokhari was fully dismissed by the Court of Appeal for Ontario. Bokhari, terminated for cause in 2021, had previously lost an arbitration claiming wrongful dismissal, which resulted in a total cost award of approximately C$2.81 million plus interest. Additional court-awarded costs have raised the amount due to over C$3 million. Quantum BioPharma has initiated U.S. collection proceedings, resulting in a judgment entered in its favor by the U.S. District Court for the Eastern District of Pennsylvania. Bokhari’s appeal is ongoing with a stay in place, backed by a supersedeas bond of more than $2.8 million.
Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee, Celly Nutrition Corporation, secured a strategic partnership with the Asian American Trade Associations Council (“AATAC”) to accelerate retail expansion of unbuzzd, a beverage aimed at reducing blood alcohol levels and restoring mental clarity. The collaboration will focus on promoting unbuzzd ’s “On-the-Go Powder Stick Packs” through AATAC’s vast network, which spans over 80,000 retail locations, including major chains like 7-Eleven, Shell and Chevron. The agreement is expected to significantly boost sales and consumer reach in the health and wellness space.
TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), today announced its licensee – Celly Nutrition Corporation (“Celly Nutrition”), the company behind unbuzzd™ – the beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms – has secured a landmark partnership with the Asian American Trade Associations Council (“AATAC”) to expand the retail availability of unbuzzd™, increase sales, and recruit new customers. This partnership will focus on unbuzzd™’s convenient “On-the-Go Powder Stick Packs” which have been scientifically proven to accelerate the reduction of blood alcohol levels and restore mental alertness.
Quantum BioPharma (NASDAQ: QNTM) has announced that its licensee, Celly Nutrition Corporation, is launching the alcohol-mitigating beverage unbuzzd in Puerto Rico through FUSION Distribution Group. The science-backed product, which speeds up alcohol metabolism and eases hangover symptoms, will be sold in “On-the-Go Powder Stick Packs” and distributed across major retailers including Walmart, Walgreens, and Costco. FUSION’s network spans Puerto Rico, the Caribbean, and parts of Central and South America.
Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region
Quantum BioPharma (NASDAQ: QNTM) a biopharmaceutical company advancing innovative biotech assets, announced a joint clinical study with Massachusetts General Hospital to evaluate a novel PET imaging technique for tracking myelin integrity in multiple sclerosis (MS) patients. The study will assess [18F]3F4AP PET scans as a biomarker for demyelination, complementing MRI scans in both progressive and relapsing-remitting MS. The technique may enhance diagnostics in trials involving remyelinating and neuroprotective drugs, including Quantum’s Lucid-MS, which has shown promise in preserving the myelin sheath in preclinical models.
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, announces that on March 31, 2025 it has entered into a joint clinical study with Massachusetts General Hospital (MGH) scientists to validate a novel positron emission tomography (PET) imaging technique to monitor myelin integrity and demyelination in people with multiple sclerosis (MS).
